Sensex

Thursday, October 21, 2010

**[investwise]** MARKET OUTLOOK, NIFTY RANGE, FREE CALL & TRADING STRATEGY FOR 22.10.2010

 
__._,_.___
Recent Activity:
*****************************************
http://in.groups.yahoo.com/group/investwise/

INVESTMENTS IN INDIA
We are low-risk, long-term investors. 

Stocks, mutual funds and the entire investment gamut.  Only financing/investment avenues in India will be discussed. 

For any assistance, questions or improvement ideas, contact investwise-owner@yahoogroups.co.in

****************************************************************

NEW! ==== Check our LINKS and FILES sections for a world of information. REGULARLY UPDATED.

NEW! ==== Check "Tracklist" in Links and Files sections for Investment Ideas.

****************************************************************
.

__,_._,___

Fwd: [stock_win_india] ROCKET STOCK….. POCHIRAJU INDUSTRIES LTD (BSE Code: 532803) AT 25/- TARGET OF 50/-

 


ROCKET STOCK….. POCHIRAJU INDUSTRIES LTD (BSE Code: 532803) AT 25/- TARGET OF 50/-

STOCK  : POCHIRAJU INDUSTRIES LTD Trading in BSE CODE : 532803

CMP : 25/- Promoters and Mutual funds Buying Heavily….. Increasing Stake

Target : 50/- to 90/- in Short term and Medium terms

Equity  : 17 Cr

Promoters  Holding : 30% ; FII's, Financial Institutions and Body Corporate : 23%; Public Only 45%

Face Value : 10/-

EPS : 6.5/-  for 2009-10 and Estimate d EPS for Full Year 2010-11 above 9/- ( Expansion Income will Add)

PE Just 3 Average PE for This Industry is 23, If we take minimum PE 10 Stock will reach 90/-++++++++ in Medium Term.

Book Value: 50/-

Reserves : 69.6 Cr (Per share = 69.6 Cr / 1.7 Cr Shares = Rs. 40.9/-)

Debt : 1 Cr Only Almost Debt Free.

Website : pochiraju dot co dot in

Pochiraju Industries Ltd Planning to Expanding Business in Pharma division and Biotech and Life Sciences Division  very Aggressively.

Pochiraju Industries Ltd Having Good Land Bank and Valuable Assets.

Pochiraju Industries Ltd Sock Will go 50/- to 90/- range in Short term and Medium Term, Like SE Investment (Call Given at 175/- Now including Bonus and Stock split 1250/-) and Bihar Tubes Ltd (Call Given at 57/- Now 165/-).

For 2009-10 Year Posted Net Income of 43.35 Cr and Net Profit of 11.25 Cr with Equity 17 Cr. As per This EPS is 6.5/- But in coming Quarters Expanding Income will add So Expecting EPS for 2010-11 is 9/- (Expanding Income will Add), Stock Trading at 24/- PE just 3 Industry PE is 23. As per this Stock will zoom to 50/- to 90/- levels in 2 to 6 Months time. Because Company Having Good Value with Small Equity and Good Promoters Holding and Good Assets and Good Financial Position and Good Future Plans.

Recently Pochiraju Industries Ltd Issue of 40,00,000 Convertible share warrants to the promoters on preferential basis for Expansion plans. Company having many Plans in  three core businesses viz. Agriculture, Pharmaceuticals andBio Pharma. Company having Huge Land Value. Its Very Strong Fundamental Stock. Future MultiBagger Stock. Excellent Pick. Public having very less shares. So will reach 50/- to 90/- soon.

In this Market Correction Time Buy Good Fundamental Stocks Like Pochiraju Industries Ltd and hold it will get good return No risk at all like this stocks.

Go Through this Full Report for Company Business, Value, Future Growth and Plans Everything in This Report, you will get Full Idea and Value of this Stock; In Future Definitely will go Multibagger and Stock will go Higher.

Pochiraju Industries Ltd (PIL) was established in 1995, initially incorporated as Pochiraju Flori Tech Ltd. The Corporate strategy of the company is to create multiple drivers of growth anchored on its core competencies .

The company is currently focusing on three business segments – Agri Business, Pharmaceuticals and Bio-Technology & Life Sciences. The organizational structure of the company is designed for effective management of multiple business, while retaining focus on each one of them.

Pharmapil is the Pharma Division of Pochiraju Industries Ltd (PIL), operating its range of Pharmaceutical Formulations on a National Level through aggressive, dynamic and committed field force of over 250 Medical Representatives. Pharmapil will have two divisions, the General and the Specialty divisions and market products in tablet, capsule, liquid, injectable, powder and ointment dosage forms.

Biopil is the Biotechnology Division of PIL. A state of art plant is under construction spread over 3.86 acres of land in the S. P. Biotechnology Park situated at Turkapally, Shamirpet, Hyderabad. This plant shall utilize cell fusion techniques, hybidomas recombinant DNA technology, protein engineering and structure based molecular design which are part of modern Biotechnology. The product range shall include Biosimilar products, such as Erythropoietin, G-CSF, Interferon Alpha, Interferon Beta, Human Growth Hormone and Recombinant Human Insulin. Biopil will have its own in house Research and Development Laboratory attached to a Common Quality Control, Documentation and Quality Assurance Laboratory.

Agropil is the Agricultural Division of PIL. From a modest start of 3 hectare of green house, it has gradually expanded its floriculture business to 6 hectare of green house and has established its presence in domestic as well as overseas markets. It will be engaged in developing hybrid varieties and genetically modified seeds, bio-fertilizers, bio-pesticides and plant growth stimulants in agriculture.

Biotech and Life Sciences Division

As a major diversification, the company is setting up a state of the modern art multi product and multi utility Bio-tech and Bio-pharma facility of International Standards to develop, manufacture and market strategically selected injectables, bio-parenterals including Oncology Products. Construction of this unit is under progress at the S.P.Biotechnology Park situated at Turkapally, Shameerpet, Hyderabad. This plant shall utilize cell fusion techniques, hybridomas recombinant DNA technology, protein engineering and structure based molecular design which are part of modern Biotechnology. The product range shall include Biosimilar products, such as Erythropoietin, G-CSF, Interferon Alpha, Interferon Beta, Human Growth Hormone and Recombinant Human Insulin.

The company's proposed manufacturing facilities will produce sterile injectables. The facilities proposed to be set up will be as per cGMP standards and strictly adhere to European, Australian and US FDA standards to cater and catch the opportunity of contract manufacturing for leading Biopharma MNCs arising as a result of WTO agreements after 2005 and also growing global generic markets.

On site chemical and microbiological analytical laboratories as well as ultra modern packing and warehousing facilities are being created. The company is adapting global standard operating procedures and systems, attract and retain qualified personnel so as to enable it to meet the latest cGMP and US FDA requirements and guidelines.

As specialists in the manufacture of Biosimilars, Biologicals, Therapeutic Proteins, Monoclonal Antibody the company proposes to offer the following full service solutions for our contract manufacturing customers.

  • Bioprocessing /purification of active materials
  • Scale up
  • Formulation development
  • Validation
  • Packing design
  • QC/QA testing
  • Regulatory affairs

Pharma Division

Pharmapil aims to help the people to lead healthier lives with specific objectives; delivering affordable and accessible medication to all parts of the World. Headquartered in India and aiming to become Global Pharmaceutical Company with Good Manufacturing Practices (GMP).

Producing a wide range of Quality and Affordable Formulations in Branded and Generic product segments, our main thrust is brand building through focused promotional activity. The company has the needed product portfolios in India, spanning key therapeutic areas, including the Cardio-vascular, neuro, diabetes Management, Respiratory, Anti-infectives, Gastro-intestinal, Dermatology, NSAIDS, Antibacterial, Antibiotics and Nutritional life style management products like Vitamins, minerals, Antiobesity drugs & Probiotics.

 

Strategy :

Pharmapil is focused on increasing the momentum in the branded formulation and generic segments in its key markets through organic and inorganic growth routes. It continues to evaluate acquisition opportunities in India and emerging into developed markets to accentuate its business and competitiveness.

 

R&D :

Pharmapil views its R&D Capabilities as a vital component of its business strategy that provides the company with a sustainable, long term competitive advantage. The R& D will focus on New Drug Discovery Research (NDDR) and New Drug Delivery System (N.D.D.S)

The company has acquired 8 acres of land in APIIC industrial estate Nadikudi, Gunturdistrict, Andhra Pradesh where in its state of the art US FDA compliance Bulk API unit is coming up with a capital outlay of Rs. 4500.00 lakhs.

 

The company has obtained all the necessary approvals for the proposed unit.

• Land Development and civil construction is under progress

• Major equipment has been identified and orders are being placed.

• The company has approached Nationalised Banks for the required term loan andworking capital.

 

Products:

The API division is focusing on the development of Anti-cancer, Anti-Allergic,Anti-ulcer and cholesterol lowering drugs. The process technology for the above API isalready developed by the In-house R&D group. Identification of basic raw materialsuppliers for the API manufacturing is under progress.

The company is also developing in house process technologies for about ten latestmolecules in the anticancer, anti-cholesterol, antibacterial segments and is planning tofile DMF for the same in the next 2 to 4 years time.

Agro Division

Pochiraju Industries Limited has its floriculture operations as a 100% EOU division cultivating, processing and exporting cut flower roses. The company's main production farm is at Satyamangalam village, Hosur taluq, Dharmapuri district, T.N.

Presently the company cultivates latest Dutch variety roses in green houses under controlled environment and is in operation since October 1999. The company is known for its quality flowers and committed deliveries in domestic and export markets. The customers are wholesalers, importers and retail outlets.

Research & Development

The strength of any Biotech company can be assessed by its Research and Development program. With an eye towards the global market, Biopil has an independent R&D Facility that provides the following services:

  • Protein Expression in Mammalian Cell System
  • Bioprocess development on Pilot Scales
  • Hybridoma Technology & Antibody production
  • Monoclonal Antibody
  • Gene cloning, Cell Line Development
  • Proteomics, Genomics and Analytical Biochemistry

The R&D laboratory has all the facilities available to offer for the above. Staffed with a highly proficient R&D team, this laboratory is equipped with the latest instrumentation to perform optimally. The R&D is geared to up scale processes systematically to ensure smooth transition of technology at commercial levels.

Pochiraju Industries Limited having Lot Expansion Plans in Fututre. Its a Multibagger stock. Just buy and hold 1 year will get 5 times Return like SE Investments Ltd (This Stock I have Recommended at 175/- levels after that reached 1200/- levels including Bonus and Split).

Positive Points for this stock for Up moving:

 

1)  Company focusing on three business segments – Agri Business, Pharmaceuticals and Bio-Technology & Life Sciences. company Circle people. Mutual Funds and Operators are accumulating at current price. Because Company Stock Good Value to buy at 25/- Good Profit making company and Book Value at 50/- and Good Assets.

2)  Equity is very small at 17 Cr promoters Holding 30%

3)  Company recently going to Expansion Plans for Business in Pharma and Bio tech Segments.

4)  Good Profit Making Company for 2009-10 EPS 6.5/- and Expecting EPS for 2010-11 is above 9/-because Expansion income will add next Quarters.

5)  Company having Good Book Value 50/- and Good Land Bank and Good Assets.

6)  Company having lot of Expansion Plans in Pharma and Bio-Tech.

7) FII's Eyes in this stock. Allready 8% holding If they will start buy Stock will zoom to 90/- levels like SE Investment (Call Given at 175/- Now including Bonus and Split 1250/-) and Bihar Tubes Ltd (Call Given at 57/- Now 165/-)

8) Risk Free at Current Market Price, Its very Cheap price Trading at 24/- Compare to companies Reserves, Assets and Value and Equity and Profits and Future Plans and power Generation.

9) This Stock is not Participated this Market Rally. So Operators, Mutual Funds and FII';s eye's in this stock.

 

Happy Invest ……….. Good Fundamentals and will give good returns from 100% to 500% returns with short and medium terms and Long terms.

 



 

Fw: L&T Infrastructure Finance Limited - Tax Saving Bonds

 
 
L&T Infrastructure Finance Company Limited, a 100% subsdiary of L&T Limited and registered with RBI as an Infrastructure Finance Company has come out with a public issue of Tax Saving Bonds.
  • Issue open already & closes on 02/11/2010.
  • Issue size of Rs.200 Crs. with an option to retain oversubscription upto Rs.500 Crs.
  • Income Tax benefit u/s. 80-CCF upto Rs.6,180/- for an investment of Rs.20,000/-
  • The Income Tax benefit is over and above 80-C, 80-CCC & 80-CCD.
  • Face Value of the Bond is Rs.1,000/- and minimum investment should be 5 Bonds
  • Maturity after 10 years & Lock in period is 5 years.
  • Buyback option available after 5 years & 7 years.
  • 7.50% interest under 5 year buyback option & 7.75% interest under 7 year buyback option.
  • Physical & Demat options available. NO TDS for interest under Demat option.
  • "CARE AA+" rating by CARE & LAA+ rating by ICRA.
  • Very attractive tax adjusted yield of more than 17% ( Annual interest / 5 year buyback option )

For more information, Please Click here.

For further informations and application forms, kindly contact your nearest branch of Integrated. For list of branches visit http://www.iepindia.com/contact.aspx